Oral EPI 7386 Trial TT

Phase 1/2 Study of EPI-7386 in Combination with Enzalutamide in Metastatic Castration-Resistant Prostate Cancer- Andrew Laccetti

Alicia Morgans is joined by Andrew Laccetti to discuss data on the combination of enzalutamide with the next-generation antigen EPI-7386 in chemotherapy-exposed patients with castration resistance in prostate cancer (CRPC) prior to exposure to any androgen receptor (AR) pathway inhibitor. EPI-7386 represents a new approach to disrupting the androgen receptor signaling pathway, the primary driver o...

Oral EPI-7386 Monotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer - Russell Pachynski

Alicia Morgans is joined by Russell Pachynski to discuss EPI-7386, a first-in-class N-terminal domain androgen receptor (AR) inhibitor that suppresses androgen activity through a novel mechanism of action. Trial of this agent in a first-in-human study in heavily pre-treated patients with metastatic castration-resistant prostate cancer (mCRPC). Dr. Pachynski provides an overview of this section of...